ArticlePublic health in practice (Oxford, England)2026
A propensity score-matched study including 250,000 patients with Factor V Leiden shows significantly increased mortality in comparison with individuals without thrombophilia.
Article in Public health in practice (Oxford, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Factor V Leiden (FVL) is a common inherited thrombophilia that increases the risk of venous thromboembolism (VTE). However, its effect on all-cause mortality remains uncertain, and previous studies yielded conflicting results. Objectives: To assess the association between FVL and all-cause mortality using a large international database, including age- and sex-stratified analyses. Study design: Retrospective propensity score-matched cohort study using real-world electronic health records. Methods: We analyzed electronic health records from the TriNetX Global Health Research Network, comparing 241,572 patients with FVL to 20,779,115 patients without thrombophilia. One-to-one propensity score matching for age was applied. Incidences of VTE and all-cause mortality were compared over a 19-year follow-up. Subgroup analyses were performed for female patients and three age categories: <20, 20-50, and >50 years. Results: FVL was significantly associated with both VTE (OR: 9.325; 95% CI: 9.109-9.546) and all-cause mortality (OR: 1.423; 95% CI: 1.396-1.451). The mortality risk was particularly elevated in young females (<20 years: OR: 9.681; 20-50 years: OR: 2.345) and attenuated in older females (>50 years: OR: 1.432). Kaplan-Meier analyses showed significantly reduced survival probabilities in FVL-positive patients across all subgroups. Conclusions: This large-scale real-world study indicates that FVL is not only a major risk factor for thrombosis but also associated with increased all-cause mortality-particularly among young women. These findings may have implications for screening and risk stratification in selected populations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.